CEbiotech.com - Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Sandoz begins Phase III clinical trial for biosimilar adalimumab

Sandoz begins Phase III clinical trial for biosimilar adalimumab

Publish date: 2013-12-24

Sandoz, the global leader in biosimilars, announced it has initiated a Phase III clinical trial with its biosimilar version of adalimumab (AbbVie’s HUMIRA®) – the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn’s disease.

Tags: biosimilars , clinical trials , Sandoz , adalimumab

This is Sandoz’s eighth Phase III trial initiation across six compounds.

  • Sandoz advances leading biosimilars pipeline by strengthening Immunology portfolio
  • Global program marks Sandoz’ sixth biosimilar molecule to enter Phase III testing
  • Trial will support registration in the U.S. and European Union

The aim of the study is to demonstrate equivalent efficacy, similarity, and immunogenicity of the Sandoz product versus HUMIRA® in patients with moderate to severe plaque-type psoriasis. Sandoz is working closely with physicians and patients on this global trial, which spans 12 countries across Europe, the United States and Asia including Japan.

Psoriasis affects approximately 3% of the world's population. There is significant unmet need in psoriasis with between nine and 30 percent of patients with severe psoriasis receiving no treatment at all2.

Because psoriasis is a chronic condition that often requires lifelong management, treatment can become a significant financial strain for many patients and healthcare systems,” said Professor Dr. Peter van de Kerkhof, Chairman of the Department of Dermatology at the Radboud University Nijmegen Medical Centre in The Netherlands and President of the International Psoriasis Council (IPC) Board of Directors. “A high-quality and clinically proven biosimilar version of adalimumab could play a meaningful role in alleviating cost burdens related to this disease.”

“This latest advancement in our pipeline represents our unwavering commitment to expanding patient access to biologics – particularly in disease areas where there is a significant need for more treatment choices,” said Mark McCamish, M.D., Ph.D., and Head of Global Biopharmaceutical & Oncology Injectables Development at Sandoz. “We look forward to bringing a high-quality and affordable biosimilar version of adalimumab to individuals around the world living with psoriasis and other debilitating autoimmune diseases such as rheumatoid arthritis.”

“Adalimumab will be a key building block in our growing Immunology portfolio, which includes other biosimilar candidates currently in Phase III trials such as etanercept (Amgen’s Enbrel®) and rituximab (Roche's Rituxan®/MabThera®),” said Ameet Mallik, Sandoz’ Head of Biopharmaceuticals and Oncology Injectables. “This key development milestone further strengthens our global leadership in biosimilars and builds on our industry-leading pipeline.”

About Sandoz

Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the rapidly growing generics industry. Sandoz employs over 26,000 employees in more than 140 countries, offering broad range of over 1,000 high-quality, affordable products that are no longer protected by patents. With USD 8.7 billion in sales in 2012, Sandoz holds the #1 position globally in biosimilars as well as generic injectables, ophthalmics, dermatology and antibiotics as well as strong positions in the treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments, and hormone therapies. Sandoz develops, produces, and markets these medicines along with pharmaceutical and biotechnological active substances. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003 , Sandoz has benefitted from strong growth of its acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).


Source: Sandoz.com

Comments:

Add comment
Guest
2016-04-03 05:26:43 +0200
My name is Jessica Luis, and I base in USA...My life is back!!! After 1 years of Broken marriage, my husband left me with two kids . I felt like my life was about to end i almost committed suicide, i was emotionally down for a very long time. Thanks to a spell caster called Dr Mohammed, which i met online. On one faithful day, as I was browsing through the internet,I came across allot of testimonies about this particular spell caster. Some people testified that he brought their Ex lover back, some testified that he restores womb,cure cancer,and other sickness, some testified that he can cast a spell to stop divorce and so on. i also come across one particular testimony,it was about a woman called Sonia,she testified about how he brought back her Ex lover in less than 2 days, and at the end of her testimony she dropped Dr Mohammed's e-mail address. After reading all these,I decided to give it a try. I contacted him via email and explained my problem to him. In just 48hours, my husband came back to me. We solved our issues, and we are even happier than before Dr Mohammed, is really a gifted man and i will not stop publishing him because he is a wonderful man... If you have a problem and you are looking for a real and genuine spell caster to solve all your problems for you. Try High monicaspiritualtemple@gmail.com anytime, he might be the answer to your problems. Here's his contact: monicaspiritualtemple@gmail.com or call him +2348134493948
Guest
2016-04-03 03:43:43 +0200
'After being in relationship with Wilson for seven years,he broke up with me, I did everything possible to bring him back but all was in vain, I wanted him back so much because of the love I have for him, I begged him with everything, I made promises but he refused. I explained my problem to someone online and she suggested that I should contact a spell caster that could help me cast a spell to bring him back but I am the type that don't believed in spell, I had no choice than to try it, I meant a spell caster called Dr Zuma zuk and I email him, and he told me there was no problem that everything will be okay before three days, that my ex will return to me before three days, he cast the spell and surprisingly in the second day, it was around 4pm. My ex called me, I was so surprised, I answered the call and all he said was that he was so sorry for everything that happened, that he wanted me to return to him, that he loves me so much. I was so happy and went to him, that was how we started living together happily again. Since then, I have made promise that anybody I know that have a relationship problem, I would be of help to such person by referring him or her to the only real and powerful spell caster who helped me with my own problem and who is different from all the fake ones out there. Anybody could need the help of the spell caster, his email: spiritualherbalisthealing@gmail.com or call him +2349055637784 you can email him if you need his assistance in your relationship or anything. CONTACT HIM NOW FOR SOLUTION TO ALL YOUR PROBLEMS'
See also
On 23rd February Immunotech Laboratory announced $2M funding approval from its associate Bulgarian Immunotech P... Read more
Tags: bulgaria , medicine , pharmaceutical , clinical trials
Aurigon Life Science is a full service contract research organisation offering optimized and tailor-made soluti... Read more
Tags: hungary , germany , CRO , clinical trials ,
Transylvanian scientists are on the verge of inventing the artificial blood. In the Cluj-Napoca, the second mos... Read more
Tags: blood , artificial blood , blood substitutes , romania , preclinical , clinical trials